You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
The company believes that the reduction in staff and marketing costs for its testing services will reduce its annual pre-tax expenses by about $4 million.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
The new assays — one targeting 17 genes and one targeting 77 genes — are based on the CAPP-Seq technology developed by Stanford University
The company added three genes to its panel and said it has improved its detection limits, although validation data for these new performance numbers is not yet published.
The South San Francisco, California-based company was founded by Dennis Lo to use noninvasive methods for early detection of cancer and other diseases.